Moderna-Merck Vaccine Cuts Melanoma Recurrence by 42% — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna and Merck co-developed the personalized mRNA vaccine intismeran autogene, which targets tumor-specific neoantigens and reduced the risk of melanoma recurrence by 42% compared to standard therapy
- Patients with melanoma in the clinical trial lived significantly longer without cancer returning, meeting the study’s key endpoint, according to the drugmakers
- The success of intismeran autogene demonstrates the therapeutic potential of mRNA technology beyond infectious diseases, extending it to individualized cancer treatment
- Oncologists view the trial results as an important advance for melanoma treatment, citing the meaningful delay in disease recurrence
Why it matters: Melanoma patients now have a promising new tool to prevent recurrence, and the 42% reduction in risk sets a benchmark for future cancer vaccines. The result validates mRNA’s expansion beyond pandemics into precision oncology, with Moderna and Merck positioned to lead in a high-stakes emerging market.
Ask SkimNews
